Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Double-Blind Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Cobitolimod as an Induction and Maintenance Therapy in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

NCT04985968 is registered in ClinicalTrials.gov with InDex Pharmaceuticals as lead sponsor.

NCT NCT04985968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04985968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Double-Blind Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Cobitolimod as an Induction and Maintenance Therapy in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis
Lead sponsor
InDex Pharmaceuticals
Phase
Phase 3
Overall status
Terminated
Start date
November 24, 2021
Completion date
December 20, 2023
Enrollment
171 (actual)
Sites
203

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis